BRPI1010087A2 - método para tratamento de doenças - Google Patents

método para tratamento de doenças

Info

Publication number
BRPI1010087A2
BRPI1010087A2 BRPI1010087A BRPI1010087A BRPI1010087A2 BR PI1010087 A2 BRPI1010087 A2 BR PI1010087A2 BR PI1010087 A BRPI1010087 A BR PI1010087A BR PI1010087 A BRPI1010087 A BR PI1010087A BR PI1010087 A2 BRPI1010087 A2 BR PI1010087A2
Authority
BR
Brazil
Prior art keywords
animal
treating diseases
provides
comprises administering
method comprises
Prior art date
Application number
BRPI1010087A
Other languages
English (en)
Inventor
Bar-Or David
Original Assignee
Dmi Acquisition Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dmi Acquisition Corp filed Critical Dmi Acquisition Corp
Publication of BRPI1010087A2 publication Critical patent/BRPI1010087A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

a invenção fornece um método para inibir hiperpermeabilidade vascular em um animal necessitando disso. o método compreende a administração de uma quantia de inibição de hiperpermeabilidade vascular de um composto de danazol ao animal. a invenção também fornece um método para modular o citoesqueleto de uma célula endotelial em um animal. o método compreende a administração de uma quantidade efetiva de um composto de danazol ao animal.
BRPI1010087A 2009-06-22 2010-06-22 método para tratamento de doenças BRPI1010087A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21918509P 2009-06-22 2009-06-22
US31535010P 2010-03-18 2010-03-18
PCT/US2010/039458 WO2010151530A1 (en) 2009-06-22 2010-06-22 Method for treatment of diseases

Publications (1)

Publication Number Publication Date
BRPI1010087A2 true BRPI1010087A2 (pt) 2019-07-16

Family

ID=43354875

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010087A BRPI1010087A2 (pt) 2009-06-22 2010-06-22 método para tratamento de doenças

Country Status (24)

Country Link
US (4) US9233113B2 (pt)
EP (7) EP2554171B1 (pt)
JP (2) JP5833549B2 (pt)
KR (1) KR101877041B1 (pt)
CN (3) CN102481304A (pt)
AU (1) AU2010264524B2 (pt)
BR (1) BRPI1010087A2 (pt)
CA (2) CA2781771A1 (pt)
DE (1) DE202010017530U1 (pt)
DK (6) DK2554172T3 (pt)
EA (1) EA027524B1 (pt)
ES (6) ES2523068T3 (pt)
HR (1) HRP20130123T1 (pt)
HU (1) HUE028212T2 (pt)
IL (1) IL216951A (pt)
MX (2) MX336436B (pt)
MY (1) MY160127A (pt)
NZ (2) NZ597030A (pt)
PL (6) PL2554171T3 (pt)
PT (5) PT2425839E (pt)
SG (7) SG2014008163A (pt)
SI (1) SI2326332T1 (pt)
WO (1) WO2010151530A1 (pt)
ZA (1) ZA201109278B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2803357B1 (en) 2004-06-25 2020-11-18 The Johns-Hopkins University Angiogenesis inhibitors
JP5544458B2 (ja) * 2005-07-12 2014-07-09 アンピオ ファーマシューティカルズ，インコーポレイテッド 疾病を治療するための医薬製品の製造においてトリロスタンｉｉｉを使用する方法及びトリロスタンｉｉｉを含む医薬製品
EP2445350A4 (en) * 2009-06-22 2012-12-26 Dmi Acquisition Corp METHOD AND PRODUCTS FOR THE TREATMENT OF DISEASES
NZ597030A (en) 2009-06-22 2013-10-25 Dmi Acquisition Corp Method for treatment of diseases
PH12014500684A1 (en) * 2011-10-07 2014-05-12 Ampio Pharmaceuticals Inc Treatment of rhinitis
CN104995300B (zh) * 2012-10-02 2018-07-17 百年癌症药物与细胞生物学研究所 Rna活性和血管通透性的调节
AU2013361338A1 (en) * 2012-12-19 2015-08-06 Ampio Pharmaceuticals, Inc. Method for treatment of diseases
JP6057333B2 (ja) * 2013-02-25 2017-01-11 国立大学法人浜松医科大学 血管透過性亢進抑制作用の評価方法
US9880778B2 (en) 2015-11-09 2018-01-30 Google Inc. Memory devices and methods
US11813262B2 (en) 2017-11-04 2023-11-14 Massachusetts Institute Of Technology Compositions and methods to increase muscular strength

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL104564C (pt) 1958-07-23
US3135743A (en) 1960-06-29 1964-06-02 Sterling Drug Inc Steroido[2. 3-d]isoxazoles and preparation thereof
GB1123770A (en) 1966-11-15 1968-08-14 Sterling Drug Inc 2-cyano-3-oxo-steroids
US4160027A (en) * 1977-12-20 1979-07-03 Sterling Drug Inc. Steroid cyanoketones and intermediates
FR2502098A1 (fr) 1981-03-23 1982-09-24 Huret & Fils Dispositif perfectionne de fixation d'un derailleur sur une patte de cadre
US4994443A (en) * 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US5714481A (en) * 1983-08-02 1998-02-03 Research Corporation Technologies, Inc. Derivatives of 5-androsten-17 ones and 5-androstan-17-ones
US4617299A (en) 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4837212A (en) * 1984-11-15 1989-06-06 University Of Miami Treatment of hemolytic anemia with danazol
US4975537A (en) * 1985-10-23 1990-12-04 The Upjohn Company Δ9(11) -angiostatic steroids
EP0244178A3 (en) 1986-04-28 1989-02-08 Iolab, Inc Intraocular dosage compositions and method of use
DE3738620A1 (de) 1987-11-13 1989-05-24 Luderschmidt Christoph Verwendung von ethisterone zur topischen behandlung von akne oder androgenetischer alopezie
US5407926A (en) 1987-12-29 1995-04-18 Alcon Laboratories, Inc. Ophthalmic composition
JP2680614B2 (ja) 1988-08-01 1997-11-19 日清製粉株式会社 ダナゾール組成物
US5990099A (en) * 1988-10-31 1999-11-23 Alcon Laboratories, Inc. Angiostatic agents and methods and compositions for controlling ocular hypertension
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
KR0181264B1 (ko) * 1989-07-07 1999-03-20 라브리 페르낭 성스테로이드 활성 억제용 안드로겐 유도체
DK0533703T3 (da) 1990-06-11 2000-08-14 Alcon Lab Inc Anvendelse af steroider til hæmning af angiogenese
US5972922A (en) * 1990-06-11 1999-10-26 Alcon Laboratories, Inc. Steroids which inhibit angiogenesis
JPH04149132A (ja) 1990-10-13 1992-05-22 Bairon Boeki Kk ダナゾール水溶液
JPH0735335B2 (ja) 1991-02-28 1995-04-19 五十嵐 正雄 子宮内膜症の治療薬
DK0593520T3 (da) * 1991-06-18 2000-04-03 Theramex Forbindelser med indhold af steroider og deres anvendelse til behandling af glaucom
CA2123405C (en) 1991-11-22 2008-01-15 Abbot F. Clark Angiostatic steroids
US5770592A (en) 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5679666A (en) * 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
GB9200210D0 (en) 1992-01-07 1992-02-26 British Bio Technology Compounds
CA2133966C (en) * 1992-04-21 1997-09-09 David A. Sullivan Ocular androgen therapy in sjogren's syndrome
ES2068742B1 (es) 1993-02-11 1995-11-16 Uriach & Cia Sa J Nuevos derivados de piridinio.
US5770589A (en) * 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
US6060462A (en) 1993-10-20 2000-05-09 Dupont Pharmaceuticals Company Electrophilic peptide analogs as inhibitors of trypsin-like enzymes
US5646136A (en) * 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
AU704591B2 (en) 1994-04-04 1999-04-29 William R. Freeman Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
WO2002096927A2 (en) 2001-05-29 2002-12-05 Ribozyme Pharmaceuticals, Incorporated Ribozyme based treatment of female reproductive diseases
US5885591A (en) 1996-07-02 1999-03-23 Johnson & Johnson Consumer Products, Inc. Personal lubricant compositions
US5929111A (en) * 1996-12-18 1999-07-27 Alcon Laboratories, Inc. A-seco steroids effective at treating ophthalmic pathological neovascularization and controlling intraocular pressure
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
WO1998043647A1 (en) * 1997-03-28 1998-10-08 Massachusetts Institute Of Technology, Inc. Regulation of amyloid precursor protein (app) expression by estrogenic compounds
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
EP0939124A3 (en) 1998-02-24 2001-03-21 Smithkline Beecham Plc MGBP1 sequences
GB9807809D0 (en) 1998-04-09 1998-06-10 Multimed Ltd Compositions comprising ethisterone or its derivatives
US6645954B2 (en) * 1998-04-09 2003-11-11 Multimed Limited Compositions comprising ethisterone or its derivatives
EP1104302A4 (en) 1998-07-10 2006-08-09 Retmed Pty Ltd PREVENTIVE TREATMENT OF NEOVASCULARIZATION IN MAKULAR GENERATION
US20040063719A1 (en) * 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
EP1022027A1 (en) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
EP1074634B1 (en) 1999-07-09 2002-10-02 Institut Pasteur De Lille Method for the diagnosis or the prognosis of Alzheimer disease therapeutical composition for preventing or treating Alzheimer disease
US6610674B1 (en) * 1999-09-28 2003-08-26 University Of Pennsylvania Method of treating inflammatory conditions with progesterone analogs
DE60040876D1 (de) * 1999-10-21 2009-01-02 Alcon Inc Medikamentenzuführeinrichtung
WO2001030337A2 (en) 1999-10-22 2001-05-03 Orbon Corporation Ophthalmic formulation of dopamine antagonists
US6562369B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers
US6632818B2 (en) 2000-01-12 2003-10-14 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
GB2345851B (en) 2000-01-18 2004-05-26 Gavin Paul Vinson A combination of trilostane or keto-trilostane and an anti-oestrogen for the treatment of an oestrogen-dependent cancer or tumour
US20020055512A1 (en) * 2000-01-21 2002-05-09 Cortendo Ab. Compositions for delivery of a cortisol antagonist
EP1938799B1 (en) 2000-03-10 2013-05-08 Insite Vision Incorporated Compositions for treating and preventing posterior segment ophthalmic disorders and use thereof
CA2774959C (en) 2000-08-04 2016-05-31 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
US20040082557A1 (en) * 2001-01-26 2004-04-29 Wajszczuk Charles Paul Methods for treating estrogen-dependent disorders
AU2002244247B2 (en) 2001-03-01 2007-12-13 Harbor Biosciences, Inc. Use of certain steroids for treatment of blood cell deficiencies
GB2375958B (en) * 2001-04-09 2005-03-02 George Margetts The use of steroids to lower the levels of cortisol
US6936599B2 (en) * 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
US20030003144A1 (en) * 2001-05-01 2003-01-02 Keller Brian C. Sustained release formulations for nifedipine, dextromethorphan, and danazol
FR2825277B1 (fr) 2001-05-30 2004-10-15 Oreal Composition cosmetique et/ou dermatologique et/ou pharmaceutique contenant au moins un compose ihnibiteur de l'enzime 3, b-hsd
US20030050291A1 (en) * 2001-06-12 2003-03-13 Yadon Arad Adrenal enzyme inhibitors
US20030232798A1 (en) * 2001-06-12 2003-12-18 Yadon Arad Adrenal enzyme inhibitors
CA2456034A1 (en) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Sustained-release medicines
JP2006506321A (ja) * 2002-04-11 2006-02-23 チルドレンズ メディカル センター コーポレーション 血管透過性亢進を阻害する方法
US20040138187A1 (en) * 2002-08-28 2004-07-15 Reading Christopher L. Therapeutic treatment methods
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
ES2263072T3 (es) 2002-12-18 2006-12-01 Laboratoires Besins International Tratamiento de la mastalgia con 4-hidroxi tamoxifeno.
CA2511217A1 (en) * 2002-12-20 2004-07-15 Chakshu Research, Inc. Ophthalmic formulation for the prevention and treatment of ocular conditions
EP1578421A4 (en) 2003-01-02 2009-04-22 Femmepharma Holding Co Inc PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF DISEASES AND BREAST CONDITIONS
CN100342856C (zh) * 2003-04-10 2007-10-17 上海医药工业研究院 达那唑半固体骨架制剂的组合物
GB2400554B (en) 2003-04-16 2007-04-18 George Margetts Treatment of angiotensin II-induced cardiovascular disease
WO2004103406A1 (ja) 2003-05-26 2004-12-02 Japan Science And Technology Agency 血小板の減少または増加を伴う疾患の治療用組成物
GB0313612D0 (en) * 2003-06-12 2003-07-16 Novartis Ag Organic compounds
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
EP1691795A2 (en) * 2003-12-03 2006-08-23 LifeCycle Pharma A/S Pharmaceutical compositions comprising danazol
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
US20050143362A1 (en) * 2003-12-31 2005-06-30 Mclane Michael W. Danazol for treatment of hypogonadism in the adult male
US7442681B2 (en) * 2004-02-10 2008-10-28 University Of Virginia Patent Foundation Method of inhibiting vascular permeability
EP1720573A4 (en) 2004-02-27 2008-04-02 Centocor Inc METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH IL-13
NZ550088A (en) 2004-04-06 2009-08-28 Angiogenetics Sweden Ab Angiogenesis-affecting compounds and methods of use thereof
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
EP2803357B1 (en) 2004-06-25 2020-11-18 The Johns-Hopkins University Angiogenesis inhibitors
GB2420281A (en) 2004-11-22 2006-05-24 Stegram Pharmaceuticals Ltd Topical formulations for use in the treatment or prevention of dermatological conditions
GB2421183A (en) 2004-12-17 2006-06-21 Stegram Pharmaceuticals Ltd Topical formulations for use in the treatment or prevention of skin cancers
WO2006082588A2 (en) 2005-02-07 2006-08-10 Pharmalight Inc. Method and device for ophthalmic administration of active pharmaceutical ingredients
EP2500031A3 (en) 2005-02-24 2012-12-26 Joslin Diabetes Center, Inc. Compositions and Methods for Treating Vascular Permeability
AU2006218654A1 (en) 2005-03-02 2006-09-08 Nascent Pharmaceutical. Inc. Combination therapy for topical application
JP5544458B2 (ja) * 2005-07-12 2014-07-09 アンピオ ファーマシューティカルズ，インコーポレイテッド 疾病を治療するための医薬製品の製造においてトリロスタンｉｉｉを使用する方法及びトリロスタンｉｉｉを含む医薬製品
US8404643B2 (en) * 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US20070173538A1 (en) * 2005-12-23 2007-07-26 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20100330148A1 (en) 2006-03-20 2010-12-30 The Johns Hopkins University Mehods and compositions for inhibiting impdh-1 isoform 1
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
US8071779B2 (en) * 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
CN101024082A (zh) 2007-04-06 2007-08-29 张士东 一种全面预防和治疗心脑血管疾病复方药及其应用
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
WO2009036108A1 (en) * 2007-09-13 2009-03-19 Children's Medical Center Corporation Methods and compositions for inhibiting vascular leakage
US20110142914A1 (en) 2007-12-06 2011-06-16 Cytotech Labs, Llc Inhalable compositions having enhanced bioavailability
US8217047B2 (en) * 2008-05-27 2012-07-10 Dmi Acquisition Corp. Therapeutic methods and compounds
EP2445350A4 (en) * 2009-06-22 2012-12-26 Dmi Acquisition Corp METHOD AND PRODUCTS FOR THE TREATMENT OF DISEASES
NZ597030A (en) 2009-06-22 2013-10-25 Dmi Acquisition Corp Method for treatment of diseases
PH12014500684A1 (en) 2011-10-07 2014-05-12 Ampio Pharmaceuticals Inc Treatment of rhinitis
AU2013361338A1 (en) 2012-12-19 2015-08-06 Ampio Pharmaceuticals, Inc. Method for treatment of diseases

Also Published As

Publication number Publication date
WO2010151530A1 (en) 2010-12-29
MY160127A (en) 2017-02-28
EP2326332A1 (en) 2011-06-01
PT2554171E (pt) 2014-11-06
PL2425839T3 (pl) 2015-03-31
PT2554172E (pt) 2014-11-07
MX2011013777A (es) 2012-04-20
EP2326332A4 (en) 2011-11-16
EP2425839B1 (en) 2014-08-13
ES2523769T3 (es) 2014-12-01
EP2326332B1 (en) 2012-11-14
EA027524B1 (ru) 2017-08-31
HK1153127A1 (en) 2012-03-23
SG2014009807A (en) 2014-04-28
PL2554171T3 (pl) 2015-03-31
EP2554172B1 (en) 2014-08-13
ES2554688T3 (es) 2015-12-22
PL2554174T3 (pl) 2016-03-31
ES2523821T3 (es) 2014-12-01
EP2554172A1 (en) 2013-02-06
SG2014008163A (en) 2014-04-28
DE202010017530U1 (de) 2012-03-28
HUE028212T2 (en) 2016-12-28
JP5833549B2 (ja) 2015-12-16
CN107050036A (zh) 2017-08-18
IL216951A0 (en) 2012-02-29
US20120077789A1 (en) 2012-03-29
DK2554172T3 (da) 2014-11-17
CA2781771A1 (en) 2010-12-29
EP2554170A1 (en) 2013-02-06
ES2612748T3 (es) 2017-05-18
US9987292B2 (en) 2018-06-05
JP2012530784A (ja) 2012-12-06
US20160175326A1 (en) 2016-06-23
DK2554171T3 (da) 2014-11-17
CN106109475A (zh) 2016-11-16
US20120035147A1 (en) 2012-02-09
HRP20130123T1 (hr) 2013-03-31
AU2010264524B2 (en) 2015-03-19
MX336436B (es) 2016-01-19
PT2326332E (pt) 2013-01-28
JP2015214575A (ja) 2015-12-03
CN102481304A (zh) 2012-05-30
PL2326332T3 (pl) 2013-05-31
NZ597030A (en) 2013-10-25
HK1176003A1 (en) 2013-07-19
KR20120102574A (ko) 2012-09-18
CA2751002C (en) 2012-09-11
EP2554171B1 (en) 2014-08-13
ES2523068T3 (es) 2014-11-20
EP2554174B1 (en) 2015-09-02
SG176939A1 (en) 2012-01-30
EA201200036A1 (ru) 2012-08-30
EP2554174A1 (en) 2013-02-06
DK2425839T3 (en) 2014-11-17
KR101877041B1 (ko) 2018-07-10
US8227457B2 (en) 2012-07-24
IL216951A (en) 2017-08-31
EP2425839A1 (en) 2012-03-07
PL2554172T3 (pl) 2015-03-31
NZ615941A (en) 2015-05-29
SI2326332T1 (sl) 2013-03-29
CA2751002A1 (en) 2010-12-29
US20100324005A1 (en) 2010-12-23
SG2014008155A (en) 2014-04-28
PT2554174E (pt) 2015-12-15
DK2554173T3 (en) 2017-01-16
ES2398322T3 (es) 2013-03-15
SG2014008171A (en) 2014-04-28
EP2554173A1 (en) 2013-02-06
DK2554174T3 (da) 2015-12-07
EP2554173B1 (en) 2016-10-05
US9233113B2 (en) 2016-01-12
SG2014009799A (en) 2014-04-28
SG2014009781A (en) 2014-04-28
AU2010264524A1 (en) 2012-01-19
PL2554173T3 (pl) 2017-06-30
DK2326332T3 (da) 2013-03-04
ZA201109278B (en) 2013-05-29
EP2554171A1 (en) 2013-02-06
HK1176870A1 (en) 2013-08-09
PT2425839E (pt) 2014-11-17

Similar Documents

Publication Publication Date Title
BRPI1010087A2 (pt) método para tratamento de doenças
EA201390347A1 (ru) Лечение заболеваний
JO2998B1 (ar) مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
MX386489B (es) Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
CR20120413A (es) Derivados de fumarato de ácido graso y sus usos
BR112012007747A2 (pt) Compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
UY33314A (es) Derivados de acido 1-amino-2-ciclopropiletilboronico
IN2014MN01183A (pt)
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
CR20110560A (es) Métodos de tratamiento para tumores sólidos
PL3482767T3 (pl) Enzymatyczna terapia zastępcza ze zwiększaniem dawki do leczenia niedoboru kwaśnej sfingomielinazy
CR20140027A (es) Inhibidores de la tirosina-quinasa de bruton
IN2015DN01197A (pt)
MX2012001134A (es) Composiciones y metodos para inhibicion de la via jak.
IN2015DN01161A (pt)
BR112016029781A2 (pt) composições e métodos para inibir a expressão de gene de alfa-1 antitripsina
MX2014007969A (es) Hidroxiamidas de ácido cinámico como inhibidores de la histona desacetilasa 8.
BR112015003729A8 (pt) Composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
CO6511222A2 (es) Derivado de idenona y composición famacéutica que comprende el mismo
MX2011010616A (es) Metodos para tratar edema relacionado a isquemia-reperfusion.
PH12015501561A1 (en) Method of treatment of diseases
BR112013033836A2 (pt) terapia de combinação
EA201200764A1 (ru) Производные хиназолина
BR112014002712A8 (pt) método para tratamento da esquizofrenia

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DAS PRIORIDADES US 61/315,350 E US 61/219,185 REIVINDICADAS NO PCT/US2010/039458, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O, ITEM 28 DO ATO NORMATIVO 128/97 E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013. ESTAS PERDAS SE DERAM PELO FATO DE O DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DO PEDIDO PCT (?DMI ACQUISITION CORP.?) SER DISTINTO DAQUELES QUE DEPOSITARAM AS PRIORIDADES REIVINDICADAS E NAO FORAM APRESENTADOS OS DOCUMENTOS COMPROBATORIOS DE CESSAO NO PRAZO LEGAL, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 6O, ITEM 27 DO ATO NORMATIVO 128/97 E NO ART. 2 DA RESOLUCAO INPIPR 179/2017.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2534 DE 30-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B25B Requested transfer of rights rejected

Owner name: DMI ACQUISITION CORP. (US)

Free format text: INDEFERIDO(S) O(S) PEDIDO(S) DE TRANSFERENCIA(S) CONTIDO(S) NA PETICAO 860140171646 DE 13/12/2014 EM VIRTUDE DO DESPACHO PUBLICADO NA RPI NO 2550 DE 19/11/2019.

B350 Update of information on the portal [chapter 15.35 patent gazette]